3 Reasons to Buy Bristol-Myers Squibb

Shares of Bristol-Myers Squibb , one of the largest pharmaceutical companies in the world, have been on a steady climb since the start of 2013. While Bristol is still facing headwinds from the patent expiration of its blockbuster drug, Plavix, recent clinical trial data have reignited investor enthusiasm for Bristol's long-term prospects. In the following segment from The Motley Fool's health care show, analysts David Williamson and Max Macaluso discuss three reasons investors might consider buying this pharma stock.